Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Downturn Hit UK Biotech In 2023 But New Pension Funds Could Fuel Growth

Executive Summary

Funding for UK biotechs shrank again last year but sector leaders see hope of green shoots in 2024.

You may also be interested in...



AstraZeneca To Partner With Quell In Buzzing Treg Field

AstraZeneca has paid $85m upfront to develop Tregs against two autoimmune conditions, type 1 diabetes and inflammatory bowel disease

Bayer Saddles Up For Bicycle Radioconjugate Pact

The German major is paying $45m upfront to get access to Bicycle’s synthetic peptides for the discovery and development of multiple targeted radioconjugates in oncology.

Abingworth Adds Stakes To Gilead’s Trodelvy Gamble

The venture capital firm is putting $210m into NSCLC trials for the antibody drug conjugate – with an opportunity in patients who fail on first line immunotherapy the most likely target.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC149686

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel